Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • ELISA
  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

Cytokeratin 8

  • Product Code: X1732M
  • Size: 100 µg
  • Availability: In Stock In Stock
  • Price (USD): $335

Cat #

X1732M		 Quantity:      

Data Sheet

Product Name

Cytokeratin 8

Host/Source

Mouse

Clone

M20

Isotype

IgG1

Product Type

Monoclonal Antibody

Reactivity

Human, Mouse

Applications

Western Blot, Immunohistochemistry, Immunocytochemistry, Flow Cytometry

Purification

Protein A/G Chromatography

Size

100 µg

Price (USD)

$335

Background

Cytokeratins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 – 7.8. The individual human cytokeratins are numbered 1 to 20. The various epithelia in the human body usually express cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays. Cytokeratin 8 belongs to the type B (basic) subfamily of high molecular weight keratins and exists in combination with keratin 18. Keratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas.

Immunogen

Hybridoma produced by the fusion of splenocytes from mice immunized with a keratin isolated from the human breast carcinoma cell line MCF-7 and mouse myeloma cells.

Positive Control

Antibody reacts with glandular epithelial cells (endocrine and exocrine) as well as mesothelial cells of the digestive, respiratory and urogenital tract and most adenocarcinomas derived from these cells.

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Database Links:

SwissProtP11679Mouse
SwissProtP05787Human

References

1. Van Muijen, G. N., et al. (1987). Coexpression of intermediate filament polypeptides in human fetal and adult tissues, Lab Invest 57, 359-69.
2. Van Muijen, G. N., et al. (1987). Differentiation-related changes of cytokeratin expression in cultured keratinocytes and in fetal, newborn, and adult epidermis, Exp Cell Res 171, 331-45.
3. Schaafsma, H. E., et al. (1989). Distribution of cytokeratin polypeptides in epithelia of the adult human urinary tract, Histochemistry 91, 151-9.
4. Smedts, F., et al. (1990). Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia, Am J Pathol 136, 657-68.
5. Ramaekers, F., et al. (1990). Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas, Am J Pathol 136, 641-55.
6. Schaafsma, H. E., et al. (1990). Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression, Am J Pathol 136, 329-43.
7. Ivanyi, D., et al. (1990). Keratin subtypes in carcinomas of the uterine cervix: implications for histogenesis and differential diagnosis, Cancer Res 50, 5143-52.
8. Wetzels, R. H., et al. (1991). Basal cell-specific and hyperproliferation-related keratins in human breast cancer, Am J Pathol 138, 751-63.
9. Ku, N. O., et al. (2001). Keratin 8 mutations in patients with cryptogenic liver disease, N Engl J Med 344, 1580-7.
10. Waseem, A., Karsten, U., Leigh, I.M., Purkis, P., Waseem, H. and Lane, B. (2004). Conformational changes in the rod domain of human keratin 8 following heterotypic association with keratin 18 and its implication for filament stability. Biochemistry 43, 1283-95.